The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 30, Issue 5, 2014, Pages 367-371

  Kocer, Derya ^a   Bayram, Fahri ^b   Diri, Halit ^b  

^a Department of Clinical Biochemistry Training and Research Hospital ^*  (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Metformin; Polycystic ovary syndrome; PON1 activity; Small dense LDL C

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; ENDOTHELIN 1; GLUKOFEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MALONALDEHYDE; METFORMIN; NITRIC OXIDE; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ARYLDIALKYLPHOSPHATASE; ESTRADIOL; FOLLITROPIN; PROGESTERONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LUTEINIZING HORMONE BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; ENDOTHELIN-1; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LUTEINIZING HORMONE; MALONDIALDEHYDE; METFORMIN; NITRIC OXIDE; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; YOUNG ADULT;

EID: 84898918811     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.887063     Document Type: Article

References (37)

1. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004;60:1-17
2. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med 2009;10:83-90
3. Yki-Järvinen H. Insulin resistance and endothelial dysfunction. Best Pract Res Clin Obstet Gynaecol 2003;17:411-30
4. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular prevention. Eur J Int Med 2006;17:77-80
5. Dejager S, Pichard C, Giral P, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol 2001;54:455-62
6. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006;147:193-201
7. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005;43:19-29
8. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-7
9. Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002;181-2:219-22
10. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-90
11. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471-8
12. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. The Rotterdam ESHRE/ ASRM - Sponsored PCOS Consensus Workshop Group. Fertil Steril 2004;81:19-25
13. Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375-9
14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9
15. Friedewald Wi, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-505
16. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995;41: 892-6
17. Eckerson EW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Gen 1983;35:214-27
18. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, dense LDL. J Lipid Res 2003;44: 2193-201
19. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005;152: 749-56
20. Orio Jr F, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normalweight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005;90:6072-6
21. Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010;33:246-51
22. Orio Jr F, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 4588-93
23. Lin AL, Gonzalezn Jr R, Carey KD, Shain SA. Estradiol-17 affects estrogen receptor distribution and elevates progesterone receptor content in baboon aorta. Arteriosclerosis 1986;6:495-504
24. Dong F, Zhang X, Wold LE, et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 2005;145:323-33
25. Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002;40:1213-32
26. Bonnefont-Rousselot D, Raji B, Walrand S, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003;52:586-9
27. Pavlovic D, Kocic R, Kocic G, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab 2000;2:251-6
28. Yilmaz M, Bukan N, Ayvaz G. The effects of rosiglitazone and metformin on oxidative stres and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005;20: 3333-40
29. Nielsen F, Mikkelsen BB, Nielsen JB, et al. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-14
30. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006;21:104-8
31. Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007;52: 879-83
32. Bin Ali A, Zhang Q, Lim YK, et al. Expression of major HDL-associated antioxidant. Free Radic Biol Med 2003;34:824-9
33. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Int Med 1991;151:1925-33
34. Ohira M, Miyashita Y, Ebisuno M. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2007;78: 34-41
35. Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome. Fertil Steril 2006;86:S20-1
36. Orio Jr F, Palomba S, Cascella T, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2-5
37. Orio F, Manguso F, Di Biase S, et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007;157: 69-73.